CAI — Caris Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $5.20bn
- $4.78bn
- $812.03m
Annual cashflow statement for Caris Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -341 | -282 | -68.1 |
| Depreciation | |||
| Non-Cash Items | 23.4 | 16.8 | 162 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -7.13 | -29.1 | -33.1 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -276 | -245 | 83.2 |
| Capital Expenditures | -22.3 | -8.44 | -16.3 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | 237 | 61.4 | 0 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | 215 | 52.9 | -16.3 |
| Financing Cash Flow Items | -2.3 | -1.06 | -26.3 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 10.1 | 200 | 665 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -51.1 | 8.02 | 732 |